Department of Anesthesiology, Yale School of Medicine, New Haven, CT.
Anesthesiology Institute, Cleveland Clinic Foundation, Cleveland, OH.
Mayo Clin Proc. 2022 Feb;97(2):375-396. doi: 10.1016/j.mayocp.2021.11.010.
Neurologic diseases are prevalent in patients undergoing invasive procedures; yet, no societal guidelines exist as to best practice in management of perioperative medications prescribed to treat these disorders. The Society for Perioperative Assessment and Quality Improvement tasked experts in internal medicine, anesthesiology, perioperative medicine, and neurology to provide evidence-based recommendations for preoperative management of these medications. The aim of this review is not only to provide consensus recommendations for preoperative management of patients on medications for neurologic disorders, but also to serve as an educational guide to perioperative clinicians. While, in general, medications for neurologic disorders should be continued preoperatively, an individualized approach may be needed in certain situations (eg, holding anticonvulsants on day of surgery if electroencephalographic mapping is planned during epilepsy surgery). Pertinent interactions with commonly used drugs in anesthesia practice, as well as considerations for targeted laboratory testing or perioperative drug substitutions, are addressed as well.
神经疾病在接受有创性操作的患者中较为常见;然而,目前尚不存在针对治疗这些疾病的围手术期药物管理的最佳实践的社会指南。围手术期评估和质量改进协会责成内科、麻醉学、围手术期医学和神经病学方面的专家提供这些药物术前管理的循证建议。本综述的目的不仅是为神经障碍患者的药物术前管理提供共识建议,而且也是为围手术期临床医生提供教育指南。虽然一般来说,神经障碍药物应在术前继续使用,但在某些情况下可能需要个体化方法(例如,如果计划在癫痫手术中进行脑电图描记,则在手术当天停用抗惊厥药物)。本文还讨论了与麻醉实践中常用药物的相关相互作用,以及针对靶向实验室检测或围手术期药物替代的注意事项。